Reagentia en instrumenten voor immunologie, celbiologie en moleculaire biologie.
 
> Ince Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince OCMI-Le) (Liquid)

Ince Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince OCMI-Le) (Liquid)

Afdrukken Afdrukken
Log in alstublieft

Referentie 506391-500ml

Formaat : 500ml

Merk : US Biological

Meer informatie aanvragen

Neem contact op met een lokale distributeur :


Telefoonnummer : +1 850 650 7790

506391 Ince Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince OCMI-Le) (Liquid)

Clone Type
Polyclonal
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze/-20°C

Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince)||Suggested Usage:|PRIMARY HUMAN OVARIAN CARICINOMA CELL LINES|Endrometrioid Primary|Endrometrioid Primary|Mucinous Primary||Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...|https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/||Feb 12, 2017 - Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.||Appearance:|Red to orange, clear, complete||FOMI Bullet 1 Included (506391B, |Colorless): |Supplied as a liquid. Vortex, spin down and add whole vial to 506391. ||Storage (506391B):|Liquid is stable at 4°C.||FOMI Bullet 2 Included (506391C, |Pink): |Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506391.||Storage (506391C):|Liquid is stable at -20°C.||Storage and Stability (506391)|(w/o supplements):|Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.||Storage and Stability (506391) |(w/ supplements):|Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.||Country of Origin|United States||Customer supplied:|To be supplemented with 5% fetal bovine serum to media|To be supplemented with Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.||Important Note: |Cholera toxin is NOT included in the liquid media nor the bullet. Shipping regulations have made it increasingly difficult to ship. Please procure from your local supplier. Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.||Licensed by TumorGenesisTM. Manufactured for research use by US Biological.

Applications
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
References
1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive.|2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337. 3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90. 4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419. 5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.